Stockreport

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress [Yahoo! Finance]

Oculis Holding AG  (OCS) 
PDF Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for inflammation and pain following cataract surgery On-track to report topline data from OCS-02 (Licaminlimab) Phase [Read more]